← FDA DRUG APPROVALS

FDA NDA · NDA013621

PERTOFRANE

Sponsor: SANOFI AVENTIS US

APPLICATION
NDA013621
TYPE
NDA
ORIGINAL APPROVAL
1968-04-10
LATEST ACTION
1985-07-30
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Discontinued

Products

PERTOFRANEDiscontinued
DESIPRAMINE HYDROCHLORIDE 25MG · CAPSULE · ORAL
PERTOFRANEDiscontinued
DESIPRAMINE HYDROCHLORIDE 50MG · CAPSULE · ORAL

Approval history

1985-07-30Labeling · Supplement 28AP
1984-05-01Labeling · Supplement 27AP
1977-08-16Labeling · Supplement 23AP
1977-07-13Labeling · Supplement 25AP
1968-04-10Type 5 - New Formulation or New Manufacturer · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →